Skip to main content
DR REDDYS LABORATORIES LTD logo

DR REDDYS LABORATORIES LTD — Investor Relations & Filings

Ticker · RDY ISIN · US2561352038 LEI · 335800OVDPY3DVZR2798 BSE.NS Manufacturing
Filings indexed 2,316 across all filing types
Latest filing 2025-05-09 Capital/Financing Update
Country IN India
Listing BSE.NS RDY

About DR REDDYS LABORATORIES LTD

https://www.drreddys.com/

Dr. Reddy's Laboratories Ltd. is an integrated global pharmaceutical company focused on providing affordable and innovative medicines. The company's core activities include the development, manufacturing, and marketing of a broad portfolio of products. This portfolio encompasses Active Pharmaceutical Ingredients (APIs), generic and branded-generic formulations, over-the-counter (OTC) products, and biologics. In addition to its significant presence in the generics market, the company invests in the research and development of novel molecules and proprietary products, with a focus on therapeutic areas such as dermatology and neurology. Dr. Reddy's is also committed to sustainable operations, actively working to reduce its environmental footprint through initiatives in water conservation, waste reduction, and decarbonisation.

Recent filings

Filing Released Lang Actions
Grant of employee stock options
Capital/Financing Update Classification · 95% confidence The document is a disclosure under Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, regarding the grant of stock options to employees under the company's stock option schemes. It details the number of options granted, exercise price, vesting schedule, and other terms related to the stock options. There is no financial performance data, earnings information, or management discussion. The document is an announcement about a capital-related event (stock options granted), which fits the category of Capital/Financing Update (CAP). The document length is under 5,000 characters and it is not a report publication announcement or certification. Therefore, the appropriate classification is CAP with high confidence.
2025-05-09 English
Appointment of Secretarial Auditor of the Company
Regulatory Filings
2025-05-09 English
41st Annual General Meeting (AGM) of the members of the Company scheduled to be held on Thursday, July 24, 2025.
Regulatory Filings
2025-05-09 English
Recommendation of final dividend
Regulatory Filings
2025-05-09 English
Record date for purpose of determining the members eligible to receive the final dividend for the financial year ended March 31, 2025 is fixed as July 10, 2025
Regulatory Filings
2025-05-09 English
Recommendation of final dividend
Regulatory Filings
2025-05-09 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.